ArriVent BioPharma (AVBP) Research & Development (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Research & Development data on file, last reported at $37.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 38.62% year-over-year to $37.6 million; the trailing twelve-month figure through Mar 2026 stood at $129.7 million (up 5.16% YoY), and the FY2025 full-year result was $153.4 million, up 94.11% from the prior year.
• Research & Development advanced to $37.6 million in Q1 2026, from $32.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $61.3 million in Q1 2025 to a low of $10.2 million in Q1 2023.
• A 4-year average of $25.8 million and a median of $20.4 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 261.05% in 2025 and slumped 38.62% in 2026, its largest moves.
• Tracing AVBP's Research & Development over 4 years: stood at $20.0 million in 2023, then climbed by 0.76% to $20.2 million in 2024, then jumped by 59.57% to $32.2 million in 2025, then climbed by 16.91% to $37.6 million in 2026.
• Business Quant data shows AVBP's Research & Development at $37.6 million in Q1 2026, $32.2 million in Q4 2025, and $32.2 million in Q3 2025.